Baird Upgrades Arrowhead Pharma (ARWR) to Outperform
Tweet Send to a Friend
Baird analyst Joel Beatty upgraded Arrowhead Pharma (NASDAQ: ARWR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
